8 recruiting, 8 unknown, 7 completed, 7 terminated. 21 Phase 2, 19 Phase 1, 2 Early Phase 1, 1 Not applicable.
Follow Liposarcoma, Myxoid: new trials by email Literature Review of Liposarcoma, Myxoid trials Research Report on Liposarcoma, Myxoid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C, Biopsy Procedure, Biospecimen Collection - Metastatic Myxoid Liposarcoma, Metastatic Synovial Sarcoma | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 42 | 2026-11-23 | 2026-09-25 |
| N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy Biospecimen Collection, Computed Tomography, Leukapheresis - Myxoid Liposarcoma, Round Cell Liposarcoma | Early Phase 1 | Recruiting | Seth Pollack | 8 | 2026-04-13 | 2026-08-27 |
| EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma Lymphodepletion, TCR-T cells (MDG1015) - Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer | Phase 1 | Not yet recruiting | Medigene AG | 55 | 2025-07-01 | 2024-12-27 |
| A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma Mirdametinib, Palbociclib - Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 54 | 2025-02-19 | 2026-09-16 |
| First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors DS-2243a - Solid Tumors, Sarcoma | Phase 1 | Recruiting | Daiichi Sankyo | 150 | 2024-11-14 | 2026-09-04 |
| BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma BTX-A51 - Liposarcoma, Recurrent Liposarcoma | Phase 1 | Active not recruiting | Michael Wagner, MD | 24 | 2024-09-30 | 2026-07-01 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide - Synovial Sarcoma, Myxoid/Round Cell Liposarcoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 44 | 2024-03-27 | 2026-07-29 |
| START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer PeptiCRAd-1, Cyclophosphamide, Pembrolizumab - Melanoma (Skin), Triple-Negative Breast Cancer | Phase 1 | Recruiting | Valo Therapeutics Oy | 15 | 2023-02-02 | 2026-05-12 |
| BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors CAR-GPC3 T Cells - Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung | Phase 1 / Phase 2 | Active not recruiting | Sotio Biotech Inc. | 7 | 2022-10-26 | 2025-12-05 |
| Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone. Trabectedin, Pioglitazone Oral Product - Liposarcoma, Myxoid, Liposarcoma, Dedifferentiated | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 10 | 2022-02-02 | 2026-02-18 |
| A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) Seclidemstat - Ewing Sarcoma, Myxoid Liposarcoma | Phase 1 / Phase 2 | Unknown | Salarius Pharmaceuticals, LLC | 10 | 2022-01-15 | 2023-08-01 |
| Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer GSK3901961, Cyclophosphamide, Fludarabine - Neoplasms | Phase 1 | Terminated | Adaptimmune | 7 | 2021-03-09 | 2024-11-13 |
| International Prospective Registry on Local Treatment Approaches in MLS Surgery, Preoperative RT 36Gy, Preoperative RT 50Gy - Myxoid Liposarcoma | Recruiting | The Netherlands Cancer Institute | 300 | 2021-01-18 | 2022-08-30 | |
| Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma GSK3845097, Cyclophosphamide, Fludarabine - Neoplasms | Phase 1 | Terminated | Adaptimmune | 5 | 2020-12-21 | 2024-11-13 |
| Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors GSK3901961, GSK3845097, GSK4427296 - Neoplasms | Phase 1 | Terminated | Adaptimmune | 12 | 2020-12-21 | 2024-11-26 |
| Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma? Blood samples will be collected at two times : - Sarcoma | Not applicable | Completed | Institut Claudius Regaud | 60 | 2020-10-22 | 2021-12-10 |
| Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide - Neoplasms | Phase 2 | Active not recruiting | USWM CT, LLC | 103 | 2019-12-31 | 2026-08-11 |
| Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas Itacitinib, Laboratory Biomarker Analysis - Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 27 | 2019-09-30 | 2024-05-08 |
| Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma afamitresgene autoleucel (previously ADP-A2M4) - Synovial Sarcoma, Myxoid Liposarcoma | Phase 2 | Active not recruiting | USWM CT, LLC | 52 | 2019-08-13 | 2026-08-26 |
Showing 20 of 40. Sign in to see all of them.
Sarcoma, Synovial (21) · Sarcoma (19) · Liposarcoma (11) · Leiomyosarcoma (6) · Neoplasms (5) · Sarcoma, Clear Cell (4) · Carcinoma, Non-Small-Cell Lung (3) · Chondrosarcoma, Extraskeletal Myxoid (3) · Fibrosarcoma (3) · Histiocytoma, Angiomatoid Fibrous (3) · Histiocytoma, Malignant Fibrous (3) · Melanoma (3) · Myoepithelioma (3) · Neurofibrosarcoma (3)
Neoplasms by Histologic Type (40) · Neoplasms, Connective and Soft Tissue (40) · Neoplasms, Adipose Tissue (39) · Neoplasms (35) · Liposarcoma (29) · Neoplasms, Connective Tissue (24) · Sarcoma (21) · Neoplasms by Site (7) · Neoplasms, Nerve Tissue (7) · Neoplasms, Muscle Tissue (6) · Neoplasms, Bone Tissue (5) · Neoplasms, Fibrous Tissue (5) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Neoplasms, Germ Cell and Embryonal (4)
Cyclophosphamide (13) · fludarabine (7) · Trabectedin (4) · Radiation Dose Hypofractionation (3) · Biopsy (2) · Interferon-gamma (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Topotecan (2) · pembrolizumab (2) · seclidemstat (2) · ALT-803 (1) · Dexamethasone (1) · Diathermy (1) · Doxorubicin (1)
Fred Hutchinson Cancer Center (4) · USWM CT, LLC (4) · Adaptimmune (3) · Maria Sklodowska-Curie National Research Institute of Oncology (3) · M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (2) · Salarius Pharmaceuticals, LLC (2) · The Netherlands Cancer Institute (2) · Assaf-Harofeh Medical Center (1) · Daiichi Sankyo (1) · GlaxoSmithKline (1) · Grupo Espanol de Investigacion en Sarcomas (1) · Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Institut Claudius Regaud (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1)
United States (29) · Netherlands (8) · Canada (6) · France (6) · Germany (5) · Italy (4) · Spain (4) · United Kingdom (4) · Australia (3) · Poland (3) · Sweden (3) · Belgium (1) · Denmark (1) · Israel (1) · Norway (1)
Adaptimmune Patient Enquiries (3) · Seth Pollack (3) · Daniela Katz, M.D (1) · David Dr. Zhen, MD (1) · David Hong, MD (1) · Dejka Araujo, MD (1) · Edward Stadtmauer, MD (1) · Hans Gelderblom, Prof (1) · Irene De Simone (1) · Jack Singer, M.D. (1) · Jessica Gartrell, MD (1) · John Livingston, MD (1)
PMID 32002290, PMID 32269142, PMID 21642514, PMID 31143880, PMID 31215818, PMID 32029687, PMID 32077895, PMID 32827353, PMID 33180100, PMID 34260265, PMID 35507536, PMID 36624315, PMID 37794590, PMID 39836945, PMID 42141895, PMID 42194972
P30CA015704 (4), 2019 (2), K23CA175167 (2), K12CA076930 (1), P30CA060553 (1), U01CA154967 (1), UM1CA186709 (1)